KRAS and neoplasm: We previously measured plasma ctDNA levels in 100 patients with CRLM and noticed remarkably high plasma ctDNA levels in patients harboring a KRAS A146–mutated tumor, an observation that warranted further investigation.18 The current study investigated the liquid biopsy ctDNA levels for all 156 patients included.